
[Cancer Research 60, 2753-2755, June 1, 2000]
© 2000 American Association for Cancer Research
p53 Polymorphism in Human Papillomavirus-associated Esophageal Cancer1
Hidetoshi Kawaguchi2,
Shinji Ohno,
Koshi Araki,
Mitsuhiro Miyazaki,
Hiroshi Saeki,
Masayuki Watanabe,
Shinji Tanaka and
Keizo Sugimachi
Department of Surgery II, Faculty of Medicine, Kyushu University [H. K., S. O., K. A., M. M., H. S., M. W., S. T., K. S.] and Cancer Center, Kyushu University Hospital [K. S.], Fukuoka 812-8582, Japan
 |
ABSTRACT
|
|---|
Human papillomavirus type 16/18 (HPV-16/18) is implicated in the
pathogenesis of squamous cell carcinoma (SCC) of the cervix and
esophagus. The arginine allele at codon 72 of p53 was found to
be more susceptible to degradation by HPV E6 protein than is the
proline allele in vivo, thus resulting in a high
frequency of cervical SCC in individuals homozygous for arginine at the
codon. There are controversial results from several clinical studies of
cervical SCC. In the present study, encoding regions of p53 codon 72
and HPV-16/18 E6 were directly sequenced, using pairs of primary
esophageal SCC tissue and corresponding normal mucosa, which were from
75 patients (Japanese, n = 38; Chinese,
n = 37). The arginine allele alone was
detected in 70.6% (12 of 17) of HPV-positive cases but only in 43.1%
(25 of 58) of HPV-negative cases (P < 0.05). In contrast, such a significant correlation between p53
polymorphism and HPV infection was not evident in corresponding normal
mucosae. Because our findings between tumor specimens and the normal
mucosae differed, we suggest that the frequent loss of proline allele
in HPV-associated carcinogenesis of the esophagus major plays some
role. The particular type of p53 polymorphism may indicate a potential
candidate for HPV-associated SCC.
 |
Introduction
|
|---|
The
HPV3
found in the anogenital tract can be classified as either high risk or
low risk according to the association with cancer. HPV-16/18 is the
most common of the high-risk group, and
90% (1)
of
cervical SCC contain DNA of HPV-16/18 and 1020% are found in
esophageal SCC (2, 3, 4)
. HPV-16/18 encodes E6 protein, which
binds to cellular tumor-suppresser protein p53 and directs degradation
through the ubiquitin pathway (5)
. This event is mediated
by another cellular protein termed E6-AP, a component of the ubiquitin
pathway (6
, 7)
. On the basis of these experiments, it is
widely assumed that p53 is functionally inactivated by the viral E6
protein in HPV-associated cancer cells and that infection with
high-risk HPV types leads to the same phenotype as a loss of p53
function because of p53 gene mutations.
The association of p53 codon 72 polymorphism with HPV-associated
cervical SCC risk has been studied by several groups but with
inconsistent results. Storey et al. (8)
reported that the form of the p53 protein carrying an Arg residue at
this position was found to be significantly more susceptible to
in vivo degradation by the E6 protein than was the Pro form.
More importantly, the Arg allele in the codon 72 polymorphism of the
p53 gene was found to be in excess in patients with cervical
SCC. Data in the literature are controversial (9, 10, 11, 12, 13, 14)
.
A part of esophageal SCC correlates with the presence of HPV-16/18
(2
, 3) . However, p53 polymorphism in esophageal SCC has
apparently not been documented. We investigated the genotypic frequency
of p53 codon 72 polymorphism and HPV-16/18 in esophageal SCC patients
in east Asia. The data we obtained seem to be the first regarding
association of this polymorphism with HPV-associated risk for cancer of
the esophagus. In this study, we investigated the cause of the
inconsistent frequency of p53 codon 72 polymorphism in HPV-associated
SCC.
 |
Materials and Methods
|
|---|
Tissue Specimens.
Pairs of primary esophageal SCC tissue and corresponding normal mucosa
were obtained from 38 Japanese patients who underwent surgery in the
Department of Surgery II, Kyushu University Hospital, from 1993 to
1998, and from 37 Chinese patients who underwent surgery in the Chinese
Academy of Medical Sciences, Beijing, China, between 1996 and 1998. No
patient had been given prior treatment. In all cases, the
histopathological type of the tumors was squamous cell carcinoma.
Cancer tissues and well-separated normal esophageal mucosae obtained
from surgically resected esophageal SCC patients were immediately
snap-frozen, and these were kept in liquid nitrogen. Genomic DNA was
prepared by proteinase K digestion and phenol/chloroform extraction,
followed by ethanol precipitation, as described (15)
.
HPV Detection and Typing.
Purified genomic DNA was amplified by PCR for HPV-16 and HPV-18.
Oligodeoxynucleotide primers were as follows: HPV-16, forward,
5'-GAATCCATATGCTGTATGTGATAAAT-3', and reverse,
5'-GATGATCTGCAACAAGACATACATC-3'; and HPV-18, forward,
5'-ACCTGTGTATATTGCAAGACAGT-3', and reverse,
5'-TGTTTCTCTGCGTCGTTGGCT-3'. Amplified PCR products were then sequenced
on a Perkin-Elmer 310 ABI automated sequencer, using each forward
primer.
p53 Polymorphism Analysis.
Purified genomic DNA was amplified by PCR for exon 4 of p53, using
oligodeoxynucleotide primers as follows: forward,
5'-TGAGGACCTGGTCCTCTGAC-3'; and reverse, 5'-AGAGGAATCCCAAAGTTCCA-3'.
Amplified PCR products were then sequenced using the forward primer.
The Arg/Pro type was scored if the area under the guanine peak was
reduced to <50% of its cytosine allele or if the area under the
cytosine peak was reduced to <50% of its guanine area.
Statistical Analysis.
2 test was used to examine the correlation
between the p53 codon 72 polymorphism of the esophageal SCC patients
and the presence of HPV-16/18; odds ratio were also calculated.
 |
Results and Discussion
|
|---|
Frequency of HPV-16/18 among Esophageal SCC Patients.
The same 75 DNA samples (Japan, n = 38;
China; n = 37) were analyzed for the presence
of oncogenic HPV, using two independent, PCR-based methods and
type-specific (HPV-16 or -18) oligonucleotide PCR primers. HPV DNA was
detected in 17 of 75 cases (22.6%). We found no differences in the
frequency and types of HPV infection between patients from Japan and
China. These results are similar to previous reports in Japan and China
(2, 3, 4)
.
Arg Allele at the Codon 72 in HPV-associated Esophageal SCC.
Direct sequencing was done on 75 DNA samples from the tumor specimens
to analyze the association between codon 72 polymorphism and
HPV-associated esophageal SCC (Fig. 1
).

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 1. Direct sequencing of codon 72. Direct sequencing of PCR
products. Case 1, Pro/LOH or Pro/Pro; Case
2, Arg/Pro; Case 3, Arg/LOH or Arg/Arg.
|
|
Frequency of the two alleles in a series of samples of HPV-positive,
esophageal SCC was compared with frequency in the HPV-negative group.
There was a marked difference in the frequency of Pro/Arg alleles
between HPV-positive and HPV-negative groups. The p53 Arg allele alone
was detected in 12 of 17 (70.6%) of the HPV-positive group, compared
with 25 of 58 (43.1%) of the HPV-negative group. The Pro allele alone
genotype or Pro/Arg genotype was found in 5 of 17 (29.4%) of the
HPV-positive group, compared with 32 of 58 (55.2%) of the HPV-negative
group. Consequently, an individual homozygous for p53 Arg would be more
likely to develop HPV-associated esophageal SCC than would a Pro/Arg
heterozygote or a Pro homozygote (P < 0.05;
odds ratio, 3.17; 95% confidence interval, 1.029.85).
Arg Allele at the Codon 72 in the Surrounding Normal Mucosa in
HPV-associated Esophageal SCC.
The frequency of the presence of Arg allele alone from the tumor
specimen was high 12 of 17 (70.6%; Table 1
) compared with the frequency found in cases of lung cancer (16
, 17)
. This means there is the possibility of a frequent LOH in
this allele, although Story et al. (8)
hypothesized that the rate of LOH at this locus was low. To examine
this hypothesis, we analyzed normal mucosa to exclude the influence of
LOH (Table 2)
. Differences in p53 polymorphism in the corresponding normal mucosa
were nil between HPV-positive and -negative tissues
(P = 0.64; odds ratio, 1.32; 95% confidence
interval, 0.424.13). In the HPV-positive group, six of eight cases
displayed LOH in the eight patients in whom the Pro/Arg type was
detected using the corresponding normal mucosa (Tables 1
2)
.
Interestingly, all of the six LOH cases had lost the Pro allele, yet
the Arg allele was never lost (Fig. 2
).

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 2. Schema polymorphism of codon 72 in HPV-associated
esophageal SCC. Direct sequencing detected eight cases of the Arg/Pro
type of codon 72 polymorphism in the normal mucosa in HPV-positive
patients. All six with LOH had lost the Pro allele, in cases of
esophageal SCC.
|
|
The p53 tumor-suppresser protein accumulates rapidly through
posttranscriptional mechanisms and is also activated as a
transcriptional factor, thus leading to growth arrest or apoptosis when
DNA damage has occurred (18)
. The ubiquitin-dependent
proteolytic pathway plays a major role in selective protein
deregulation. The E6 oncoprotein of oncogenic HPV-16/18 uses this
cellular proteolytic system to target the p53 protein (5)
.
The E6 oncoprotein binds to a cellular protein of E6-AP, and the
E6-E6-AP complex interacts with p53, resulting in the rapid
ubiquitin-dependent degradation of p53 (19)
. The level and
half-life of p53 in E6 immortalized cell lines or in HPV-positive
cervical carcinoma cells are generally decreased (20)
.
Certain HPV types such as HPV-16/18 found in the SCC of cervix and
esophagus suggest a model by which E6 degrades cell growth control by
elimination of the p53 tumor suppresser protein and leads to
HPV-associated cervix and esophageal SCC.
Our studies revealed the potential role of the loss of the Pro allele
in HPV-associated carcinogenesis of the esophagus. The relationship
between the targeted LOH of the p53 gene and HPV infection
warrants ongoing studies.
 |
Acknowledgments
|
|---|
We thank Prof. Ru Gang Zhang (Chinese Academy of Medical
Sciences, Beijing, China) for providing the samples of esophageal SCC
from Chinese patients.
 |
FOOTNOTES
|
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This study was supported by grants from the
Ministry of Education, Science, Sports and Culture of Japan. 
2 To whom requests for reprints should be
addressed, at Department of Surgery II, Faculty of Medicine, Kyushu
University Fukuoka 812-8582, Japan. Phone: 81-92-642-5466; Fax:
81-92-642-5482; E-mail: hideto{at}surg2.med.kyushu-u.ac.jp 
3 The abbreviations used are: HPV, human
papillomavirus; SCC, squamous cell carcinoma; LOH, loss of
heterozygosity; E6-AP, E6-associated protein. 
Received 1/31/00.
Accepted 4/17/00.
 |
REFERENCES
|
|---|
-
Riou G., Favre M., Jeannel D., Bourhis J., Le Doussal V., Orth G. Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA. Lancet, 335: 1171-1174, 1990.[Medline]
-
Toh Y., Kuwano H., Tanaka S., Baba K., Matsuda H., Sugimachi K., Mori R. Detection of human papillomavirus DNA in esophageal carcinoma in Japan by polymerase chain reaction. Cancer (Phila.), 70: 2234-2238, 1992.[Medline]
-
He D., Zhang D. K., Lam K. Y., Ma L., Ngan H. Y., Liu S. S., Tsao S. W. Prevalence of HPV infection in esophageal squamous cell carcinoma in Chinese patients and its relationship to the p53 gene mutation. Int. J. Cancer, 72: 959-964, 1997.[Medline]
-
Togawa K., Rustgi A. K. A novel human papillomavirus sequence based on L1 general primers. Virus Res., 36: 293-297, 1995.[Medline]
-
Scheffner M., Werness B. A., Huibregtse J. M., Levine A. J., Howley P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63: 1129-1136, 1990.[Medline]
-
Huibregtse J. M., Scheffner M., Howley P. M. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J., 10: 4129-4135, 1991.[Medline]
-
Huibregtse J. M., Scheffner M., Howley P. M. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol. Cell. Biol., 13: 4918-4927, 1993.[Abstract/Free Full Text]
-
Storey A., Thomas M., Kalita A., Harwood C., Gardiol D., Mantovani F., Breuer J., Leigh I. M., Matlashewski G., Banks L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature (Lond.), 393: 229-234, 1998.[Medline]
-
Zehbe I., Voglino G., Wilander E., Genta F., Tommasino M. Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet, 354: 218-219, 1999.[Medline]
-
Rosenthal A. N., Ryan A., Al-Jehani R. M., Storey A., Harwood C. A., Jacobs I. J. p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet, 352: 871-872, 1998.[Medline]
-
Lanham S., Campbell I., Watt P., Gornall R. p53 polymorphism and risk of cervical cancer. Lancet, 352: 14 1998.
-
Hayes V. M., Hofstra R. M., Buys C. H., Hollema H., van der Zee A. G. Homozygous arginine-72 in wild type p53 and risk of cervical cancer. Lancet, 352: 28 1998.
-
Helland A., Langerod A., Johnsen H., Olsen A. O., Skovlund E., Borresen-Dale A. L. p53 polymorphism and risk of cervical cancer. Nature (Lond.), 396: 530-531, 1998.[Medline]
-
Hildesheim A., Schiffman M., Brinton L. A., Fraumeni J. F., Jr., Herrero R., Bratti M. C., Schwartz P., Mortel R., Barnes W., Greenberg M., McGowan L., Scott D. R., Martin M., Herrera J. E., Carrington M. p53 polymorphism and risk of cervical cancer. Nature (Lond.), 396: 531-532, 1998.[Medline]
-
Tanaka S., Toh Y., Adachi E., Matsumata T., Mori R., Sugimachi K. Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation. Cancer Res., 53: 2884-2887, 1993.[Abstract/Free Full Text]
-
Murata M., Tagawa M., Kimura M., Kimura H., Watanabe S., Saisho H. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients: discrete results with smoking history. Carcinogenesis (Lond.), 17: 261-264, 1996.[Abstract/Free Full Text]
-
Kawajiri K., Nakachi K., Imai K., Watanabe J., Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis (Lond.), 14: 1085-1089, 1993.[Abstract/Free Full Text]
-
Levine A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.[Medline]
-
Scheffner M., Huibregtse J. M., Vierstra R. D., Howley P. M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell, 75: 495-505, 1993.[Medline]
-
Scheffner M., Munger K., Byrne J. C., Howley P. M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA, 88: 5523-5527, 1991.[Abstract/Free Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
Z.-Z. Zhu, A.-Z. Wang, H.-R. Jia, X.-X. Jin, X.-L. He, L.-F. Hou, and G. Zhu
Association of the TP53 Codon 72 Polymorphism with Colorectal Cancer in a Chinese Population
Jpn. J. Clin. Oncol.,
May 1, 2007;
37(5):
385 - 390.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Hong, X. Miao, X. Zhang, F. Ding, A. Luo, Y. Guo, W. Tan, Z. Liu, and D. Lin
The Role of P53 and MDM2 Polymorphisms in the Risk of Esophageal Squamous Cell Carcinoma
Cancer Res.,
October 15, 2005;
65(20):
9582 - 9587.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Omori, S. Yoshida, S. H. Kennedy, K. Negoro, S. Hamana, D. H. Barlow, and T. Maruo
Polymorphism at Codon 72 of the p53 Gene Is Not associated With Endometriosis in a Japanese Population
Reproductive Sciences,
May 1, 2004;
11(4):
232 - 236.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Bonafe, C. Ceccarelli, F. Farabegoli, D. Santini, M. Taffurelli, C. Barbi, E. Marzi, C. Trapassi, G. Storci, F. Olivieri, et al.
Retention of the p53 Codon 72 Arginine Allele Is Associated with a Reduction of Disease-Free and Overall Survival in Arginine/Proline Heterozygous Breast Cancer Patients
Clin. Cancer Res.,
October 15, 2003;
9(13):
4860 - 4864.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z.-W. Zhang, P. Newcomb, A. Hollowood, R. Feakins, M. Moorghen, A. Storey, M. J. G. Farthing, D. Alderson, and J. Holly
Age-associated Increase of Codon 72 Arginine p53 Frequency in Gastric Cardia and Non-Cardia Adenocarcinoma
Clin. Cancer Res.,
June 1, 2003;
9(6):
2151 - 2156.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K J Syrjanen
HPV infections and oesophageal cancer
J. Clin. Pathol.,
October 1, 2002;
55(10):
721 - 728.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Furihata, T. Takeuchi, M. Matsumoto, A. Kurabayashi, Y. Ohtsuki, N. Terao, M. Kuwahara, and T. Shuin
p53 Mutation Arising in Arg72 Allele in the Tumorigenesis and Development of Carcinoma of the Urinary Tract
Clin. Cancer Res.,
May 1, 2002;
8(5):
1192 - 1195.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Liu, D. P. Miller, W. Zhou, S. W. Thurston, R. Fan, L.-L. Xu, T. J. Lynch, J. C. Wain, L. Su, and D. C. Christiani
Differential Association of the Codon 72 p53 and GSTM1 Polymorphisms on Histological Subtype of Non-Small Cell Lung Carcinoma
Cancer Res.,
December 1, 2001;
61(24):
8718 - 8722.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. A. Brooks, J. A. Tidy, B. Gusterson, L. Hiller, J. ONions, M. Gasco, M. C. Marin, P. J. Farrell, W. G. Kaelin Jr., and T. Crook
Preferential Retention of Codon 72 Arginine p53 in Squamous Cell Carcinomas of the Vulva Occurs in Cancers Positive and Negative for Human Papillomavirus
Cancer Res.,
December 1, 2000;
60(24):
6875 - 6877.
[Abstract]
[Full Text]
|
 |
|